N-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide

Catalog No. :
ACNGRR584
CAS No. :
2241514-56-5
Molecular Formula :
C16H22FN5O3S
Molecular Weight :
383.45

IUPAC Name:LY3372689

N-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1mg98%$168.00Login to see priceInquiryInquiry
5mg98%$357.00Login to see priceInquiryInquiry
10mg98%$537.00Login to see priceInquiryInquiry
25mg98%$852.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide
IUPAC NameLY3372689
Molecular FormulaC16H22FN5O3S
Molecular Weight383.45
SMILESCC(NC1=NC(F)=C(CN2[C@@H](C)C[C@@H](OCC3=NOC(C)=N3)CC2)S1)=O
InChI KeyFRVXHWNHGWUTQO-CABZTGNLSA-N
SynonymCeperognastat | Formulaic Ia
CAS No.2241514-56-5
PubChem CID135260636

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACNGRR584 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNGRR584 route product structure diagram
    ACNGRR5842241514-56-5
Inquiry

2. ACNGRR584 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNGRR584 route product structure diagram
    ACNGRR5842241514-56-5
Inquiry

Comments (0)